HealthEquity, Inc. (NASDAQ:HQY) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 92.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 55,597 shares of the company’s stock after purchasing an additional 26,690 shares during the period. Los Angeles Capital Management LLC owned about 0.06% of HealthEquity worth $4,551,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after acquiring an additional 149,133 shares during the last quarter. Vaughan Nelson Investment Management L.P. lifted its position in HealthEquity by 1.8% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 616,860 shares of the company’s stock worth $53,173,000 after buying an additional 11,150 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in HealthEquity by 29.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock worth $5,535,000 after buying an additional 14,573 shares in the last quarter. Diversify Wealth Management LLC purchased a new position in HealthEquity during the second quarter worth approximately $8,182,000. Finally, Sequoia Financial Advisors LLC purchased a new position in HealthEquity during the second quarter worth approximately $1,122,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HQY has been the topic of a number of analyst reports. Barrington Research reiterated an “outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. JMP Securities restated a “market outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft lifted their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Finally, Bank of America reduced their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, HealthEquity currently has an average rating of “Buy” and an average target price of $103.83.

Insider Buying and Selling

In related news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the transaction, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Robert W. Selander sold 8,250 shares of the company’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Frank Corvino sold 1,039 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock valued at $884,517 in the last three months. 2.20% of the stock is owned by corporate insiders.

HealthEquity Price Performance

HQY stock opened at $100.27 on Tuesday. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $8.76 billion, a PE ratio of 83.56, a P/E/G ratio of 1.55 and a beta of 0.52. HealthEquity, Inc. has a 12-month low of $62.10 and a 12-month high of $100.97. The business’s fifty day moving average price is $83.57 and its 200 day moving average price is $80.60.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The firm had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. On average, sell-side analysts anticipate that HealthEquity, Inc. will post 2.27 EPS for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.